<DOC>
	<DOC>NCT01591863</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD).</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Male or female 6 months to 17 years 11 months of age, inclusive; Female subjects of childbearing potential must use adequate contraception Diagnosed with CDAD Concurrent use of oral vancomycin or metronidazole or any other effective treatments for CDAD Fulminant colitis History of inflammatory bowel disease Pregnant or breastfeeding Need for concurrent use of some Pglycoprotein inhibitors during therapy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Clostridium difficile-associated diarrhea</keyword>
	<keyword>CDAD</keyword>
	<keyword>Pediatric</keyword>
</DOC>